

Diabetic Gastroparesis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

<https://marketpublishers.com/r/D2A6519E94BFEN.html>

Date: June 2026

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: D2A6519E94BFEN

Abstracts

Diabetic gastroparesis is a chronic gastrointestinal complication that occurs when long-term diabetes damages the vagus nerve, impairing the stomach's ability to empty its contents at a normal rate. This delayed gastric emptying leads to symptoms such as nausea, vomiting, abdominal pain, bloating, early satiety, and fluctuations in blood glucose levels. In severe cases, it can result in malnutrition, dehydration, and poor glycemic control, significantly affecting quality of life. With the rising global diabetes burden, diabetic gastroparesis is becoming an increasingly critical healthcare concern. Early diagnosis and effective therapeutic intervention are essential for managing symptoms and preventing severe complications.

The Global Diabetic Gastroparesis Market is being driven by multiple key factors. The increasing prevalence of type 1 and type 2 diabetes worldwide, combined with prolonged disease duration, has amplified the incidence of diabetic gastroparesis. Advances in therapeutic options, including prokinetic agents, and investigational biologics, are improving symptom management and compliance among patients. Additionally, growing awareness among healthcare providers and patients, along with government and non-government initiatives to promote early diagnosis and management, is boosting demand for effective therapeutics.

However, the market faces significant restraints. Diagnosis remains complex due to nonspecific and overlapping symptoms, leading to underdiagnosis or misdiagnosis. Existing pharmacological options often provide only partial symptom relief, with limited long-term efficacy and safety concerns. Variability in patient response to therapies, combined with high treatment costs and lack of standardized clinical guidelines, further restricts market expansion. These challenges highlight the need for innovative treatment

approaches that target the underlying disease mechanisms.

The competitive landscape of the Global Diabetic Gastroparesis Market is shaped by leading pharmaceutical companies actively developing and commercializing novel therapies. Key players such as Evoke Pharma, Teva Pharmaceuticals, Vanda Pharmaceuticals, Eli Lilly, and Takeda are investing in the development of prokinetic drugs, antiemetic formulations, and biologics aimed at improving gastric motility and symptom relief. Strategic collaborations between pharmaceutical companies, academic institutions, and research organizations are accelerating clinical trials and regulatory approvals. The market is witnessing a gradual shift toward precision medicine and patient-centric care, emphasizing early diagnosis, optimized therapeutic strategies, and improved quality of life for patients.

Significant growth opportunities exist in the Global Diabetic Gastroparesis Market, particularly in emerging economies where diabetes prevalence is rising, and healthcare infrastructure is strengthening. Increasing R&D investments in biologics, combination therapies, and novel drug delivery systems are expanding therapeutic possibilities. Supportive government initiatives to enhance diabetes management, together with physician training programs, are fostering improved diagnostic rates and standardized care practices. These factors are expected to create a favourable environment for both established pharmaceutical companies and new entrants to capture market share in the coming decade.

Market Segmentation:

Segmentation 1: by Region

North America

Europe

Asia-Pacific

The Global Diabetic Gastroparesis Market is witnessing transformative trends that are reshaping treatment strategies. A notable trend is the increasing focus on novel pharmacological agents, including next generation prokinetics and biologics, which aim to address both symptoms and disease progression. There is also a growing interest in patient-specific treatment regimens supported by advancements in biomarkers and

companion diagnostics, enabling more precise management of gastroparesis. Additionally, digital health platforms and real-time glucose monitoring technologies are being integrated into patient care, facilitating better control of both glycaemic levels and gastroparesis symptoms. With expanding clinical research pipelines and rising investment in innovative therapies, the market is set to enter a new phase of growth and therapeutic innovation.

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

This report will be delivered in 7-10 working days.

Contents

Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note

1. GLOBAL DIABETIC GASTROPARESIS MARKET: INDUSTRY ANALYSIS

1.1 Market Overview and Ecosystem
1.2 Value chain Analysis
1.3 Key Market Trends
 1.3.1 Impact Analysis
1.4 Regulatory Landscape
1.5 Market Dynamics
 1.5.1 Overview
 1.5.2 Market Drivers
 1.5.3 Market Restraints
 1.5.4 Market Opportunities

2. GLOBAL DIABETIC GASTROPARESIS MARKET (BY REGION), VALUE (\$MILLION), 2023-2035

2.1 North America
 2.1.1 Market Dynamics
 2.1.2 Market Sizing and Forecast
 2.1.3 North America Diabetic Gastroparesis Market, by Country (\$Million), 2023-2035
 2.1.3.1 U.S.
 2.1.3.2 Canada
2.2 Europe
 2.2.1 Market Dynamics
 2.2.2 Market Sizing and Forecast
 2.2.3 Europe Diabetic Gastroparesis Market, by Country (\$Million), 2023-2035
 2.2.3.1 U.K.
 2.2.3.2 France
 2.2.3.3 Germany
 2.2.3.4 Rest-of-Europe

2.3 Asia-Pacific

2.3.1 Market Dynamics

2.3.2 Market Sizing and Forecast

2.3.3 Asia-Pacific Diabetic Gastroparesis Market, by Country (\$Million), 2023-2035

2.3.3.1 Japan

2.3.3.2 China

2.3.3.3 India

2.3.3.4 Rest-of-Asia-Pacific

2.4 Rest-of-the-World

2.4.1 Market Dynamics

2.4.2 Market Sizing and Forecast

2.4.3 Rest-of-the-World Diabetic Gastroparesis Market, by Country (\$Million), 2023-2035

2.4.3.1 Latin America

2.4.3.2 Middle East and Africa

3. GLOBAL DIABETIC GASTROPARESIS MARKET COMPETITIVE LANDSCAPE AND COMPANY PROFILES

3.1 Competitive Landscape

3.1.1 Mergers and Acquisitions

3.1.2 Partnership, Alliances and Business Expansion

3.1.3 New Offerings

3.1.4 Regulatory Activities

3.1.5 Funding Activities

3.2 Company Profiles

3.2.1 Evoke Pharma

3.2.1.1 Overview

3.2.1.2 Top Products / Product Portfolio

3.2.1.3 Top Competitors

3.2.1.4 Target Customers/End-Users

3.2.1.5 Key Personnel

3.2.1.6 Analyst View

3.2.2 Teva Pharmaceuticals

3.2.2.1 Overview

3.2.2.2 Top Products / Product Portfolio

3.2.2.3 Top Competitors

3.2.2.4 Target Customers/End-Users

3.2.2.5 Key Personnel

3.2.2.6 Analyst View
3.2.3 Others

4. RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure: Diabetic Gastroparesis Market (by Scenario), \$Million, 2024, 2030, and 2035

Figure: Global Diabetic Gastroparesis Market, 2024 and 2035

Figure: Global Diabetic Gastroparesis Market Key Trends, Impact Analysis, 2023-2035

Figure: North America Diabetic Gastroparesis Market, \$Million, 2023-2035

Figure: Europe Diabetic Gastroparesis Market, \$Million, 2023-2035

Figure: Asia-Pacific Diabetic Gastroparesis Market, \$Million, 2023-2035

List Of Tables

LIST OF TABLES

Table: Market Snapshot

Table: Market Dynamics

Table: Global Diabetic Gastroparesis Market (by Region), \$Million, 2023-2035

I would like to order

Product name: Diabetic Gastroparesis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

Product link: <https://marketpublishers.com/r/D2A6519E94BFEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D2A6519E94BFEN.html>